ATAI - Atai Life Sciences N.V.
| Previous Close | 1.7900 |
| Open | 1.7800 |
| Bid | 1.7700 x 1400 |
| Ask | 1.7800 x 2900 |
| Day's Range | 1.7600 - 1.8292 |
| 52 Week Range | 1.1400 - 4.9600 |
| Volume | |
| Avg. Volume | 1,090,944 |
| Market Cap | 292.178M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Market Exclusive
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Aurora announced the repurchase of convertible senior notes worth approximately $47 million, saving the company $2.6 million in annualized interest payments. Jushi Holdings reported preliminary Q4 and record full year 2022 financial results. Curaleaf announced $20 million acquisition in Key Takeaways; Psychedelic Sector Awakn’s proprietary treatment protocol for alcohol use disorder […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared fi
- Motley Fool
New Regulations for Psychedelics? Here's What Investors Need to Know
If you love investing in businesses that are on the bleeding edge of biotechnology, psychedelics companies are right up your alley. Despite substantial cultural baggage and significant legal hurdles, psychedelic medicines are proving themselves to be highly effective at treating mental illnesses like depression and post-traumatic stress disorder (PTSD), and that means they're likely to be quite lucrative for the developers. On July 13, the Drug Enforcement Agency (DEA) said it was scheduling a public hearing for Aug. 22, so people would have a chance to comment on a proposed rule that would move five psychedelic compounds into the Schedule 1 category.
- Simply Wall St.
Here's Why We're Not Too Worried About Atai Life Sciences' (NASDAQ:ATAI) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
